<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6380461/results/search/drugs/results.xml">
  <result pre="conjugates. Of these, 7 (tremelimumab, spartalizumab, BCD-100, omburtamab, mirvetuximab soravtansine," exact="trastuzumab" post="duocarmazine, and depatuxizumab mafodotin) are being evaluated in clinical"/>
  <result pre="more than 10 have been granted marketing approvals. In 2002," exact="adalimumab" post="became the first mAb therapeutic derived from phage display"/>
  <result pre="mogamulizumab-kpkc, moxetumomab pasudotox-tdfk, tildrakizumab-asmn. Abbreviations: CD, cluster of differentiation; CGRP," exact="calcitonin" post="gene-related peptide; dsFv, disulfide-stabilized variable fragment; EU European Union;"/>
  <result pre="in adults. Erenumab is a human IgG2 mAb that targets" exact="calcitonin" post="gene-related peptide (CGRP) receptor, thereby blocking the activity of"/>
  <result pre="patients administered mogamulizumab compared to 3.1 months for patients taking" exact="vorinostat" post="in this clinical trial. 31 Poteligeo was designated as"/>
  <result pre="or to tildrakizumab 200 mg, tildrakizumab 100 mg, placebo, or" exact="etanercept" post="50 mg (2:2:1:2; reSURFACE 2). In these trials, the"/>
  <result pre="tolerated and found to be efficacious compared with placebo and" exact="etanercept" post="in the treatment of patients with moderate-to-severe chronic plaque"/>
  <result pre="NCT03250962) of camrelizumab with or without decitabine, the addition of" exact="decitabine" post="increased the complete response rate of patients with relapsed/refractory"/>
  <result pre="factor; BCMA, B-cell maturation antigen; BLyS, B lymphocyte stimulator; CGRP," exact="calcitonin" post="gene-related peptide; MASP-2, mannose-binding protein-associated serine protease 2; TACI,"/>
  <result pre="or 3 mg brolucizumab (HAWK study only) versus 2 mg" exact="aflibercept" post="in patients with nAMD. The primary efficacy endpoint of"/>
  <result pre="nAMD. The primary efficacy endpoint of the studies, non-inferiority to" exact="aflibercept" post="(EYLEA®) in mean change in best-corrected visual acuity (BCVA)"/>
  <result pre="5.9 letters for brolucizumab 6 mg versus 5.3 letters for" exact="aflibercept" post="in the HAWK study, and 6.1 letters versus 6.6"/>
  <result pre="fluid was 24% for brolucizumab 6 mg vs. 37% for" exact="aflibercept" post="in HAWK (p = 0.0001) and 24% vs. 39%,"/>
  <result pre="-175 µm for brolucizumab 6 mg versus -149 µm for" exact="aflibercept" post="in HAWK (p = 0.0057) and -198 µm versus"/>
  <result pre="infusion in combination with standard doses of bendamustine (B) and" exact="rituximab" post="(R) or obinutuzumab in patients with relapsed or refractory"/>
  <result pre="with standard doses of bendamustine (B) and rituximab (R) or" exact="obinutuzumab" post="in patients with relapsed or refractory follicular lymphoma (FL)"/>
  <result pre="The combination of polatuzumab vedotin with R-CHP protocol (rituximab, cyclophosphamide," exact="doxorubicin" post="and prednisone) versus R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone)"/>
  <result pre="protocol (rituximab, cyclophosphamide, doxorubicin and prednisone) versus R-CHOP (rituximab-cyclophosphamide, doxorubicin," exact="vincristine" post="and prednisone) in DLBCL patients is currently being investigated"/>
  <result pre="ICARIA study (NCT02990338), the effects of isatuximab in combination with" exact="pomalidomide" post="and low-dose dexamethasone are being compared to those of"/>
  <result pre="the effects of isatuximab in combination with pomalidomide and low-dose" exact="dexamethasone" post="are being compared to those of only the chemotherapy"/>
  <result pre="(NCT02967692) evaluating the safety and efficacy of spartalizumab combined with" exact="dabrafenib" post="(a BRAF inhibitor) and trametinib (a MEK inhibitor) versus"/>
  <result pre="efficacy of spartalizumab combined with dabrafenib (a BRAF inhibitor) and" exact="trametinib" post="(a MEK inhibitor) versus matching placebo in combination with"/>
  <result pre="trametinib (a MEK inhibitor) versus matching placebo in combination with" exact="dabrafenib" post="and trametinib in previously untreated patients with BRAF V600–mutant"/>
  <result pre="MEK inhibitor) versus matching placebo in combination with dabrafenib and" exact="trametinib" post="in previously untreated patients with BRAF V600–mutant unresectable or"/>
  <result pre="plans to submit marketing applications for PDR001 in combination with" exact="trametinib" post="+ dabrafenib for the treatment of metastatic BRAF V600+"/>
  <result pre="submit marketing applications for PDR001 in combination with trametinib +" exact="dabrafenib" post="for the treatment of metastatic BRAF V600+ melanoma in"/>
  <result pre="Phase 2 L-MIND study (NCT02399085), which evaluated MOR208 combined with" exact="lenalidomide" post="in patients with relapsed or refractory DLBCL. 83 A"/>
  <result pre="primarily on the L-MIND study. 84 MOR208 with bendamustine versus" exact="rituximab" post="with bendamustine is being evaluated in the Phase 2/3"/>
  <result pre="of ublituximab and TGR-1202, a PI3K delta inhibitor, versus anti-CD20" exact="obinutuzumab" post="plus chlorambucil in untreated and previously treated CLL patients."/>
  <result pre="and TGR-1202, a PI3K delta inhibitor, versus anti-CD20 obinutuzumab plus" exact="chlorambucil" post="in untreated and previously treated CLL patients. The primary"/>
  <result pre="are evaluating the efficacy and safety of ublituximab compared to" exact="teriflunomide" post="in 440 patients with relapsing multiple sclerosis. For both"/>
  <result pre="2/3 study (NCT03470922) of anti-LAG3 relatlimab (Bristol-Myers Squibb) combined with" exact="nivolumab" post="versus nivolumab in patients with previously untreated metastatic or"/>
  <result pre="(NCT03470922) of anti-LAG3 relatlimab (Bristol-Myers Squibb) combined with nivolumab versus" exact="nivolumab" post="in patients with previously untreated metastatic or unresectable melanoma"/>
  <result pre="July 2020. ADC ‘antibodies to watch’ include mirvetuximab soravtansine (ImmunoGen)," exact="trastuzumab" post="duocarmazine (Synthon BioPharmaceuticals), and depatuxizumab mafodotin (Abbvie). Mirvetuximab soravtansine,"/>
  <result pre="first half of 2019. The safety and efficacy of anti-HER2" exact="trastuzumab" post="duocarmazine (Synthon BioPharmaceuticals) is being evaluated in the Phase"/>
  <result pre="C5 complement component 5 CCR4 CC chemokine receptor 4 CGRP" exact="calcitonin" post="gene-related peptide CHMP Committee for Medicinal Products for Human"/>
  <result pre=", Li Q , et al Tildrakizumab versus placebo or" exact="etanercept" post="for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2):"/>
  <result pre=", et al Camrelizumab (SHR-1210) alone or in combination with" exact="gemcitabine" post="plus cisplatin for nasopharyngeal carcinoma: results from two single-arm,"/>
  <result pre="al Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus" exact="cisplatin" post="for nasopharyngeal carcinoma: results from two single-arm, phase 1"/>
  <result pre="collab: Novartis Two-year data for Novartis brolucizumab reaffirm superiority versus" exact="aflibercept" post="in reducing retinal fluid in patients with nAMD ."/>
  <result pre=", et al Adding polatuzumab vedotin (POLA) to bendamustine and" exact="rituximab" post="(BR) treatment improves survival in patients with relapsed/refractory DLBCL:"/>
  <result pre="MorphoSys reports updated data from L-MIND study of MOR208 plus" exact="lenalidomide" post="in aggressive lymphoma (r/r DLBCL) . 3 13, 2018"/>
 </snippets>
</snippetsTree>
